Open Access Articles- Top Results for Bazinaprine


Systematic (IUPAC) name
Clinical data
94011-82-2 7pxN
PubChem CID 72119
ChemSpider 65096 7pxY
UNII NU8Y4C529J 7pxY
ChEMBL CHEMBL150365 7pxY
Chemical data
Formula C17H19N5O
309.366 g/mol
 14pxN (what is this?)  (verify)

Bazinaprine (SR-95,191) is an experimental drug candidate. It is a monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of depression. The drug strongly inhibits type A monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible in vivo, but not in vitro.[1] In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.[2]

See also


  1. ^ Kan, JP; Steinberg, R; Leclercq, J; Worms, P; Biziere, K (1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: Evidence for selective and reversible inhibition of monoamine oxidase type a in vivo but not in vitro". Journal of Neurochemistry 50 (4): 1137–44. PMID 3346672. doi:10.1111/j.1471-4159.1988.tb10584.x. 
  2. ^ Kan, JP; Steinberg, R; Mouget-Goniot, C; Worms, P; Bizière, K (1987). "SR 95191, a selective inhibitor of type a monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition". The Journal of Pharmacology and Experimental Therapeutics 240 (1): 251–8. PMID 3100771.